Rationale for treating epilepsy in children

Epileptic Disorders

Volumn 4, Issue SUPPL. 2, 2002, Pages

  Guerrini, Renzo ^a,d   Arzimanoglou, Alexis ^b   Brouwer, Oebele ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Children; EEG; Epilepsy syndrome; Epileptic encephalopathy; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ABSENCE; BRAIN DISEASE; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; ELECTROENCEPHALOGRAM; EPILEPSY; HUMAN; LENNOX GASTAUT SYNDROME; MYOCLONUS SEIZURE; PARENT; PRIORITY JOURNAL; RISK; SEIZURE;

ANTICONVULSANTS; BRAIN; CHILD; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENE EXPRESSION; HUMANS; TIME FACTORS;

EID: 0036816205     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (127)

1. Arzimanoglou A. Treatment options in paediatric epilepsy syndromes. Epileptic Disord 2002; 4: p. (in press).
2. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 (Suppl 3): S2-10.
3. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5-17.
4. King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure presentation: A clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet 1998; 352: 1007-11.
5. Hawkes N. Hundreds die as NHS fails child epileptics. In: The Times. 2002: London.
6. Commission in Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
7. Berkovic SF, Scheffer IE. Genetics of the epilepsies. Epilepsia 2001; 42 (Suppl 5): 16-23.
8. Guerrini R, Andermann E, Avoli M, Dobyns WB. Cortical dysplasias, genetics, and epileptogenesis. Adv Neurol 1999; 79: 95-121.
9. Guerrini R, Carrozzo R. Epilepsy and genetic malformations of the cerebral cortex. Am J Med Genet 2001; 106: 160-73.
10. Aicardi J, Arzimanoglou A. Treatment of the childhood epilepsy syndromes. In Shorvon S, Dreifuss F, Fish D, Thomas D, Edit. The Treatment of Epilepsy. Oxford: Blackwell Science Ltd, 1996: 199-214.
11. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50.
12. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13.
13. Bauer J. Seizure-inducing effects of antiepileptic drugs: A review. Acta Neurol Scand 1996; 94: 367-77.
14. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study. Epilepsia 1997; 38: 1270-4.
15. Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: A European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996; 37: 638-42.
16. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389-95.
17. Picard F, Bertrand S, Steinlein OK, Bertrand D. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 1999; 40: 1198-209.
18. Dulac O, Guerrini R. Seizure types and syndromes: Lumping or splitting. Epilepsy Res 2001; 45: 37-40; discussion 41.
19. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12.
20. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 55: 1758.
21. Dravet C, Guerrini R, Mancini J, et al. Different outcomes of epilepsy due to cortical dysplastic lesions. In Guerrini R, Andermann F, Canapicchi R, et al. Edit. Dysplasias of Cerebral Cortex and Epilepsy. Philadelphia-New York: Lippincott-Raven, 1996: 323-8.
22. Ambrosetto G, Tassinari CA. Antiepileptic drug treatment of benign childhood epilepsy with rolandic spikes: Is it necessary? Epilepsia 1990; 31: 802-5.
23. Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338: 429-34.
24. Wyllie E. Children with seizures: When can treatment be deferred? J Child Neurol 1994; 9 (Suppl 2): 8-13.
25. Camfield PR, Camfield CS. Treatment of children with "ordinary" epilepsy. Epileptic Disord 2000; 2: 45-51.
26. Donner EJ, Smith CR, Snead OC. 3rd, Sudden unexplained death in children with epilepsy. Neurology 2001; 57: 430-4.
27. Reynolds EH. The early treatment and prognosis of epilepsy. Jpn J Psychiatry Neurol 1988; 42: 429-35.
28. Oller-Daurella L, Oller LF. Influence of the "lost time" on the outcome of epilepsy. Eur Neurol 1991; 31: 175-7.
29. Paquier PF, Van Dongen HR, Loonen CB. The Landau-Kleffner syndrome or "acquired aphasia with convulsive disorder". Long-term follow-up of six children and a review of the recent literature. Arch Neurol 1992; 49: 354-9.
30. Hahn A. Atypical benign partial epilepsy/Pseudo Lennox syndrome. Epileptic Disord 2000; 2: S11-S17
31. Dalla Bernardina B, Colamaria V, Capovilla G, Bondavalli S. Nosological classification of epilepsies in the first three years of life. In: Epilepsy: An Update on Research and Therapy. New York: Alan Liss, 1983: 165-83.
32. Guerrini R, Dravet C. Severe Epileptic Encephalopathies of Infancy. In: Engel J, Pedley T, Edit. Epilepsy - Vol. 3. Philadelphia-New York: Lippincott-Raven, 1997: 2285-302.
33. Vigevano F, Di Rocco C. Effectiveness of hemispherectomy in hemimegalencephaly with intractable seizures. Neuropediatrics 1990; 21: 222-3.
34. Arzimanoglou AA, Andermann F, Aicardi J, et al. Sturge-Weber syndrome: Indications and results of surgery in 20 patients. Neurology 2000; 55: 1472-9.
35. Chauvel P, Dravet C, Dileo M, et al. The HHE syndrome. In: Luders H. Epilepsy Surgery, New York: Raven Press, 1991: 183-96.
36. Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain 1995; 118 (Pt 6): 1529-46.
37. Deonna TW. Acquired epileptiform aphasia in children (Landau-Kleffner syndrome). J Clin Neurophysiol 1991; 8: 288-98.
38. Paetau R, Kajola M, Korkman M, et al. Landau-Kleffner syndrome: Epileptic activity in the auditory cortex. Neuroreport 1991; 2: 201-4.
39. Seri S, Cerquiglini A, Pisani F. Spike-induced interference in auditory sensory processing in Landau-Kleffner syndrome. Electroencephalogr Clin Neurophysiol 1998; 108: 506-10.
40. Shewmon DA, Erwin RJ. Focal spike-induced cerebral dysfunction is related to the after-coming slow wave. Ann Neurol 1988; 23: 131-7.
41. Galanopoulou AS, Bojko A, Lado F, Moshe SL. The spectrum of neuropsychiatric abnormalities associated with electrical status epilepticus in sleep. Brain Dev 2000; 22: 279-95.
42. Lewine JD, Andrews R, Chez M, et al. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics 1999; 104 (3 Pt 1): 405-18.
43. Deonna T, Davidoff V, Maeder-Ingvar M, Zesiger P, Marcoz JP. The spectrum of acquired cognitive disturbances in children with partial epilepsy and continuous spike-waves during sleep. A 4-year follow-up case study with prolonged reversible learning arrest and dysfluency. Europ J Paediatr Neurol 1997; 1: 19-29.
44. Massa R, de Saint-Martin A, Carcangiu R, et al. EEG criteria predictive of complicated evolution in idiopathic rolandic epilepsy. Neurology 2001; 57: 1071-9.
45. Saint-Martin AD, Carcangiu R, Arzimanoglou A, et al. Semiology of typical and atypical Rolandic epilepsy: A video-EEG analysis. Epileptic Disord 2001; 3: 173-82.
46. Gordon K, Bawden H, Camfield P, Mann S, Orlik P. Valproic acid treatment of learning disorder and severely epileptiform EEG without clinical seizures. J Child Neurol 1996; 11: 41-3.
47. Levy RH, Mattson RH, Meldrum BS. Antiepileptic Drugs. 1995, New York: Raven Press.
48. Yasuhara A, Yoshida H, Hatanaka T, et al. Epilepsy with continuous spike-waves during slow sleep and its treatment. Epilepsia 1991; 32: 59-62.
49. Van Lierde A. Therapeutic data. In: Beaumanoir A, Bureau M, Deonna T, Mira L, Tassinari C. Continuous Spikes and Waves during Slow Sleep, London: John Libbey, 1995: 225-7.
50. Billard C, Autret A, Laffont F, et al. Acquired aphasia in epileptic children-four cases with electrical infraclinic status epilepticus during sleep. Rev Electroencephalogr Neurophysiol Clin 1981; 11: 457-67.
51. Larrieu JL, Lagueny A, Ferrer X, Julien J. Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam. Rev Electroencephalogr Neurophysiol Clin 1986; 16: 383-94.
52. De Negri M. Electrical status epilepticus in childhood: Neuropsychological impairment and therapeutic management. Dev Med Child Neurol 1994; 36: 183-6.
53. Boel M, Casaer P. Continuous spikes and waves during slow sleep: A 30 months follow-up study of neuropsychological recovery and EEG findings. Neuropediatrics 1989; 20: 176-80.
54. Marescaux C, Hirsch E, Finck S, et al. Landau-Kleffner syndrome: A pharmacologic study of five cases. Epilepsia 1990; 31: 768-77.
55. Lerman P, Lerman-Sagie T, Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol 1991; 33: 257-60.
56. Amann JP, Dulac O. Trials in children. Epilepsy Res 2001; 45: 133-6; discussion 137-40.
57. Aicardi J. Diseases of the Nervous System in Children. 2nd Edition, 1998, Cambridge: Cambridge University Press.
58. Riikonen R, Donner M. ACTH therapy in infantile spasms: Side effects. Arch Dis Child 1980; 55: 664-72.
59. Kusse MC, van Nieuwenhuizen O, van Huffelen AC, et al. The effect of non-depot ACTH (1-24) on infantile spasms: Dev Med Child Neurol 1993; 35: 1067-73.
60. Chiron C, Dulac O, Luna D, et al. Vigabatrin in infantile spasms. Lancet 1990; 335: 363-4.
61. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40: 1627-33.
62. Prats JM, Garaizar C, Rua MJ, Garcia-Nieto ML, Madoz P, Infantile spasms treated with high doses of sodium valproate: Initial response and follow-up. Dev Med Child Neurol 1991; 33: 617-25.
63. Chamberlain MC. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. J Child Neurol 1996; 11: 31-4.
64. Cossette P, Riviello JJ, Carmant L. ACTH versus vigabatrin therapy in infantile spasms: A retrospective study. Neurology 1999; 52: 1691-4.
65. Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57: 1416-21.
66. Riikonen RS. Steroids or vigabatrin in the treatment of infantile spasms? Pediatr Neurol 2000; 23: 403-8.
67. Lewis H, Wallace SJ. Vigabatrin. Dev Med Child Neurol 2001; 43: 833-5.
68. Lux AL, Edwards SW, Osborne JP, et al. Revised guideline for prescribing vigabatrin in children. Guideline's claim about infantile spasms is not based on appropriate evidence. BMJ 2001; 322: 236-7.
69. Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory Group. BMJ 2000; 320: 1404-5.
70. Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48: 60-4.
71. Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002; 43: 748-56.
72. Britton JW, So EL. Selection of antiepileptic drugs: A practical approach. Mayo Clin Proc 1996; 71: 778-86.
73. Guerrini R, Battini R, Ferrari AR, et al. The costs of childhood epilepsy in Italy: Comparative findings from three health care settings. Epilepsia 2001; 42: 641-6.
74. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995; 37: 97-108.
75. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282-8.
76. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000; 9: 375-9.
77. Bourgeois BF. Temporal lobe epilepsy in infants and children. Brain Dev 1998; 20: 135-41.
78. Duchowny M. Pediatric epilepsy surgery: The widening spectrum of surgical candidacy. Epileptic Disord 1999; 1: 143-51.
79. Tassi L, Colombo N, Garbelli R, et al. Focal cortical dysplasia: Neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain 2002; 125 (Pt 8): 1719-32.
80. Ferrie CD, Beaumanoir A, Guerrini R, et al. Early-onset benign occipital seizure susceptibility syndrome. Epilepsia 1997; 38: 285-93.
81. Bourgeois B, Brown L, Pellock J, et al. Gabapentin (Neurontin) monotherapy in children with benign childhood epilepsy with centrotemporal-spikes (BECTS): A 36-week, double blind, placebo-controlled study. Epilepsia 1998; 39: 163.
82. Besag FM, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991-7.
83. Arzimanoglou A, Kulak I, Bidaut-Mazel C, Baldy-Moulinier M. Optimal use of lamotrigine in clinical practice: Results of an open multicenter trial in refractory epilepsy. Rev Neurol (Paris) 2001; 157: 525-36.
84. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330-7.
85. Rosenfeld WE. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19: 1294-308.
86. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225-30.
87. Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: Roger J, Dravet C, Bureau M, et al. Epileptic Disorders in Infancy Childhood and Adolescence, London-Paris: John Libbey Eurotext, 1992: 75-88.
88. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638-42.
89. Guerrini R, Dravet C, Gobbi G, Ricci S, Dulac O. Idiopathic generalised epilepsies with myoclonus in infancy and childhood. In: Malafosse A, Genton P, Hirsch E, et al. Idiopathic Generalised Epilepsies. Clinical, Experimental and Genetic Aspects, LondonParis: John Libbey Eurotext, 1994: 267-80.
90. Kaminska A, Ickowicz A, Plouin P, et al. Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 1999; 36: 15-29.
91. Scheffer IE, Wallace R, Mulley JC, Berkovic SF. Clinical and molecular genetics of myoclonic-astatic epilepsy and severe myoclonic epilepsy in infancy (Dravet syndrome). Brain Dev 2001; 23: 732-5.
92. Genton P, Guerrini R, Dravet C. The Lennox-Gastaut syndrome. In: Meinardi H. Handbook of Clinical Neurology Vol 73. The Epilepsies, Part II, Amsterdam: Elsevier Science, 2000: 211-22.
93. Trevathan E, Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol 2002; 17 (Suppl 2): 2S9-2S22.
94. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807-12.
95. Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993; 9: 465-9.
96. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52: 1882-7.
97. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29-33.
98. Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999; 34: 91-7.
99. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: A randomized, double-blind, crossover study. Epilepsia 1998; 39: 495-501.
100. Yamatogi Y, Ohtsuka Y, Ishida T, et al. Treatment of the Lennox syndrome with ACTH: A clinical and electroencephalographic study. Brain Dev 1979; 1: 267-76.
101. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18: 25-9.
102. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998; 18: 53-5.
103. Wallace RH, Wang DW, Singh R, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet 1998; 19: 366-70.
104. Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000; 24: 343-5.
105. Sugawara T, Tsurubuchi Y, Agarwala KL, et al. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc Natl Acad Sci USA 2001; 98: 6384-9.
106. Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: A mutation in the gamma2-subunit gene. Nat Genet 2001; 28: 46-8.
107. Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11: 201-3.
108. Steinlein OK, Magnusson A, Stoodt J, et al. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Genet 1997; 6: 943-7.
109. Gambardella A, Annesi G, De Fusco M, et al. A new locus for autosomal dominant nocturnal frontal lobe epilepsy maps to chromosome 1. Neurology 2000; 55: 1467-71.
110. Phillips HA, Scheffer IE, Crossland KM, et al. Autosomal dominant nocturnal frontal-lobe epilepsy: Genetic heterogeneity and evidence for a second locus at 15q24. Am J Hum Genet 1998; 63: 1108-16.
111. Kalachikov S, Evgrafov O, Ross B, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002; 30: 335-41.
112. Guipponi M, Rivier F, Vigevano F, et al. Linkage mapping of benign familial infantile convulsions (BFIC) to chromosome 19q. Hum Mol Genet 1997; 6: 473-7.
113. Moulard B, Buresi C, Malafosse A. Study of the voltage-gated sodium channel beta 1 subunit gene (SCN1B) in the benign familial infantile convulsions syndrome (BFIC). Hum Mutat 2000; 16: 139-42.
114. Caraballo R, Pavek S, Lemainque A, et al. Linkage of benign familial infantile convulsions to chromosome 16p12-q12 suggests allelism to the infantile convulsions and choreoathetosis syndrome. Am J Hum Genet 2001; 68: 788-94.
115. Malacarne M, Gennaro E, Madia F, et al. Benign familial infantile convulsions: Mapping of a novel locus on chromosome 2q24 and evidence for genetic heterogeneity. Am J Hum Genet 2001; 68: 1521-6.
116. Scheffer IE, Phillips HA, O'Brien CE, et al. Familial partial epilepsy with variable foci: A new partial epilepsy syndrome with suggestion of linkage to chromosome 2. Ann Neurol 1998; 44: 890-9.
117. Xiong L, Labuda M, Li DS, et al. Mapping of a gene determining familial partial epilepsy with variable foci to chromosome 22q11-q12. Am J Hum Genet 1999; 65: 1698-710.
118. Guerrini R, Bonanni P, Patrignani A, et al. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: A newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. Brain 2001; 124 (Pt 12): 2459-75.
119. Guerrini R, Bonanni P, Nardocci N, et al. Autosomal recessive rolandic epilepsy with paroxysmal exercise-induced dystonia and writer's cramp: Delineation of the syndrome and gene mapping to chromosome 16p12-11.2. Ann Neurol 1999; 45: 344-52.
120. Plaster NM, Uyama E, Uchino M, et al. Genetic localization of the familial adult myoclonic epilepsy (FAME) gene to chromosome 8q24. Neurology 1999; 53: 1180-3.
121. Mikami M, Yasuda T, Terao A, et al. Localization of a gene for benign adult familial myoclonic epilepsy to chromosome 8q23:3-q24.1. Am J Hum Genet 1999; 65: 745-51.
122. Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68: 1327-32.
123. Sugawara T, Mazaki-Miyazaki E, Fukushima K, et al. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology 2002; 58: 1122-4.
124. Cossette P, Liu L, Brisebois K, et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet 2002; 31: 184-9.
125. Stromme P, Mangelsdorf ME, Shaw MA, et al. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet 2002; 30: 441-5.
126. Kinton L, Johnson MR, Smith SJ, et al. Partial epilepsy with pericentral spikes: A new familial epilepsy syndrome with evidence for linkage to chromosome 4p15. Ann Neurol 2002; 51: 740-9.
127. Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet 2002; 11: 1119-28.